Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study For Sorrento Therapeutics On Lymphatic Etanercept Delivery In Rheumatoid Arthritis Patients With Results To Be Presented At The 2022 American College Of Rheumatology Conference
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study For Sorrento Therapeutics On Lymphatic Etanercept Delivery In Rheumatoid Arthritis Patients With Results To Be Presented At The 2022 American College Of Rheumatology Conference
Nutriband Inc. (the "Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has conducted a Phase 1b clinical study for Sorrento Therapeutics, Inc. ("Sorrento") (NASDAQ:SRNE) with results to be presented at the American College of Rheumatology (ACR) Convergence 2022 Conference on November 13, 2022 as a poster abstract entitled "Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections."
亚洲网加利福尼亚州圣何塞11月13日电营养带公司(纳斯达克代码：NTRB)(纳斯达克代码：NTRBW)今天宣布，其子公司4P治疗有限责任公司(以下简称4P治疗公司)已经为索伦托治疗公司(纳斯达克：SRNE)进行了一项1b期临床研究，研究结果将以海报摘要的形式于2022年11月13日在美国风湿病学会会聚2022年会议上公布，题为《以淋巴方式递送依那西普对皮下注射反应不足的患者在标准剂量的50%对类风湿性关节炎的治疗效果显著改善》。
"We are excited about these proof of concept clinical results and the development of Sorrento's Sofusa lymphatic delivery platform for treatment of autoimmune diseases such as rheumatoid arthritis to provide hope for those patients who do not respond adequately to conventional biologic injections," said Alan Smith, Ph.D., President, 4P Therapeutics. "This success highlights the clinical regulatory capabilities of 4P Therapeutics in advancing drug delivery products for our partners."
4P治疗公司的艾伦·史密斯博士总裁说：“我们对这些概念验证临床结果以及索伦托公司用于治疗类风湿性关节炎等自身免疫性疾病的Sofusa淋巴输送平台的开发感到兴奋，这将为那些对传统生物注射没有足够反应的患者带来希望。这一成功突显了4P治疗公司在为我们的合作伙伴推进药物输送产品方面的临床管理能力。“
The abstract is available at
摘要可在以下网址查阅